Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in zucker fatty rats

Hormone and Metabolic Research

Volumn 42, Issue 10, 2010, Pages 731-735

  Miura, K ^a   Kitahara, Y ^a   Yamagishi, S ^b  

^a Pharmaceutical Research Laboratories   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

insulin resistance; nateglinide; postprandial metabolic derangements; vildagliptin

Indexed keywords

FATTY ACID; INSULIN; NATEGLINIDE; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LIPID DIET; LIVER; MALE; METABOLIC DISORDER; NONHUMAN; OBESITY; PANCREAS ISLET; PANCREAS ISLET BETA CELL; POSTPRANDIAL METABOLIC DERANGEMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER DIABETIC FATTY RAT;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; CYCLOHEXANES; DRUG THERAPY, COMBINATION; FATTY ACIDS; FORKHEAD TRANSCRIPTION FACTORS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; LIVER; MALE; METABOLIC DISEASES; NITRILES; ORGAN SIZE; PHENYLALANINE; PHOSPHORYLATION; POSTPRANDIAL PERIOD; PYRROLIDINES; RATS; RATS, ZUCKER; TRIGLYCERIDES;

ANIMALIA; RATTUS;

EID: 77956434906     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1261929     Document Type: Article

References (23)

1. Jessani S, Millane T, Lip GY. Vascular damage in impaired glucose tolerance: an unappreciated phenomenon? Curr Pharm Des 2009 15 3417-3432
2. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab 2009 10 159-163
3. Delorme S, Chiasson JL. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opin Pharmacol 2005 5 184-189
4. Bae JH, Bassenge E, Kim KB, Kim YN, Kim KS, Lee HJ, Moon KC, Lee MS, Park KY, Schwemmer M. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 2001 155 517-523
5. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002 106 1211-1218
6. Pleiner J, Schaller G, Mittermayer F, Bayerle-Eder M, Roden M, Wolzt M. FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab 2002 87 2913-2917
7. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007 298 299-308
8. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996 276 882-888
9. Pirro M, Maurige P, Tchernof A, Cantin B, Dagenais GR, Desprs JP, Lamarche B. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Qubec Cardiovascular Study. Atherosclerosis 2002 160 377-384
10. Banerjee M, Younis N, Soran H. Vildagliptin in clinical practice: a review of literature. Expert Opin Pharmacother 2009 10 2745-2757
11. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008 60 470-512
12. Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008 31 108-113
13. Azuma K, Rdikov Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008 93 459-464
14. Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J 2005 81 1-6
15. Yamagishi S, Nakamura K, Jinnouchi Y, Takenaka K, Imaizumi T. Molecular mechanisms for vascular injury in the metabolic syndrome. Drugs Exp Clin Res 2005 31 123-129 (Pubitemid 40942954)
16. Kajioka T, Miura K, Kitahara Y, Yamagishi S. Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in Zucker Fatty rats. Horm Metab Res 2007 39 889-893
17. Folch J, Sloane-Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957 226 497-509
18. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008 40 620-625
19. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2003 285 E685-E692
20. Hall R, Yamasaki T, Kucera T, Waltner-Law M, OBrien R, Granner DK. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. J Biol Chem 2000 275 30169-30175
21. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabetic Med 2005 22 674-782
22. Miyazaki Y, Akasaka H, Ohnishi H, Saitoh S, DeFronzo RA, Shimamoto K. Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects. Hypertens Res 2008 31 1357-1363
23. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003 278 471-478